Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study Research Letter

   


Authors: Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G. T.; Romancik, J.; Amoozgar, B.; Leslie, L.; Nastoupil, L. J.; Crombie, J. L.; Abramson, J. S.; Khurana, A.; Nowakowski, G. S.; Maddocks, K.; Rutherford, S. C.; Kahl, B.; Okwali, M.; Buege, M. J.; Seshan, V.; Batlevi, C. L.; Salles, G.
Title: Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
Abstract: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology
Keywords: immunohistochemistry; adult; treatment outcome; aged; retrospective studies; major clinical study; overall survival; lenalidomide; clinical trial; neutropenia; drug dose reduction; monotherapy; follow up; antineoplastic agent; progression free survival; anemia; thrombocytopenia; antineoplastic combined chemotherapy protocols; retrospective study; risk factor; febrile neutropenia; health care quality; hospitalization; disease severity; multicenter study; comorbidity; large cell lymphoma; lymphoma, large b-cell, diffuse; disease exacerbation; clinical outcome; overall response rate; diffuse large b cell lymphoma; humans; human; male; female; article; eligibility criteria; ecog performance status; tafasitamab
Journal Title: Blood
Volume: 142
Issue: 26
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2023-12-28
Start Page: 2327
End Page: 2331
Language: English
DOI: 10.1182/blood.2023021274
PUBMED: 37738563
PROVIDER: scopus
PMCID: PMC10797539
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175478290&doi=10.1182%2fblood.2023021274&partnerID=40&md5=6808367c4dd9afd71d724a803032205c
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Gilles Salles -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Venkatraman Ennapadam Seshan
    382 Seshan
  2. Connie Wing-Ching Lee Batlevi
    176 Batlevi
  3. Michael Buege
    17 Buege
  4. Gilles Andre Salles
    269 Salles
  5. Michelle Okwali
    20 Okwali
  6. David Augustus Qualls
    20 Qualls
Related MSK Work